New York, June 1, 2026, 16:02 EDT
NeuroPace Inc. stock was flat in late trade Monday. The company got U.S. Food and Drug Administration approval for ECoG Assistant, its first AI tool aimed at epilepsy clinicians.
The stock last changed hands at $16.49, down 0.3%. It moved between $15.68 and $16.73 today. Around 105,000 shares traded. The company’s market cap was about $556 million.
NeuroPace has won approval for a new software tool aimed at its RNS System, the company’s brain implant that tracks activity and responds to seizure patterns. The ECoG Assistant—ECoG meaning electrocorticography, or electrical activity on the brain’s surface—is made to help doctors sort and analyze those records faster, according to the company.
NeuroPace on Friday said it trained its ECoG Assistant on 124,450 long intracranial EEG records, all labeled by epileptologists. Intracranial EEG, or iEEG, refers to electrical signals recorded from inside the skull. Chief Medical Officer Martha Morrell said the tool gives clinicians “faster access to insights.” CEO Joel Becker called the approval proof of the company’s data “translating into practical tools for clinicians today.” Business Wire
NeuroPace is getting a live audience for its new tool this week at the American Society for Stereotactic and Functional Neurosurgery meeting in Cleveland, which started May 29 and goes through June 2. The company is also showing NAUTILUS data in idiopathic generalized epilepsy, or IGE, where seizures hit both sides of the brain instead of just one spot.
NeuroPace has sent its new Patient Data Management System, or PDMS, to the FDA and says approval could come in the second quarter of 2026. PDMS runs the software handling patient data from the RNS platform. Investors are already looking beyond the recent product news to what’s coming next on the regulatory side.
The stock didn’t see a breakout after the FDA news. Most medical-device shares stayed flat and biotech moved lower. The iShares U.S. Medical Devices ETF dipped 0.04%. The iShares Nasdaq Biotechnology ETF slid 1.4% late Monday.
The market’s move offered little support. Wall Street traded higher Monday, with the S&P 500 gaining 0.43% and the Nasdaq Composite rising 0.69%. Tech shares led. Investors watched oil prices, Middle East tensions and waited for the U.S. jobs report.
NeuroPace still depends on execution to fuel growth. The company on May 12 posted first-quarter revenue of $22.1 million. It bumped its 2026 revenue outlook to a range of $99 million to $101 million. RNS System sales grew 19.5% from the prior year to $21.7 million. Net loss under GAAP was $6.7 million.
Wall Street sentiment stays positive, but analysts aren’t all lined up. MarketBeat puts a “Moderate Buy” on the stock, based on eight analysts, with a $18.83 average price target for the next 12 months. Benzinga shows that HC Wainwright kept its buy rating on May 15, setting the target at $20. MarketBeat
Competition is intense. NeuroPace named LivaNova, which sells the VNS System, and Medtronic, which makes the DBS System, as its top neuromodulation competitors for drug-resistant focal epilepsy in its latest annual report. The company said LivaNova and Medtronic have larger sales networks, bigger product portfolios and greater financial resources.
Approval for a single AI-enabled feature may not have much immediate effect on procedure volumes, reimbursement, or hospital uptake. NeuroPace has cautioned it needs to maintain regulatory approvals, get clearances for new updates and indications, and have steady reimbursement from third-party payers. Any holdup with PDMS approval or NAUTILUS expansion could make it tougher to back up its revenue forecast.
